PAVM - PAVmed announces first human implants with the PortIO infusion system

Commercial-stage med-tech firm, PAVmed (PAVM +7.1%), is trading higher after announcing the first human implants using the company’s PortIO Intraosseous Infusion System. As part of the first-in-human study in Colombia, South America, doctors at the Clinica Porto Azul in Barranquilla have successfully implanted the device in three patients, PAVmed (NASDAQ:PAVM) said. With no complications, all patients have successfully received an infusion of fluids in line with the study protocol. “Simply stated, PortIO worked exactly as designed and intended,” Chief Medical Officer of PAVmed (PAVM) Brian J. deGuzman remarked. While the intraosseous route was widely in use to infuse fluids, medicines, etc., into bone marrow instead of a vein, “existing intraosseous devices protrude through the skin and can only be used for 48 hours or less, generally for emergency situations,” he added. Read why Seeking Alpha contributor Shareholders Unite argued PAVmed (PAVM) shares were attractive last December.

For further details see:

PAVmed announces first human implants with the PortIO infusion system